Autobio Diagnostics Co., Ltd. Class A

Autobio Diagnostics Co., Ltd. Class A

SSSE:603658
38.94
CNY
-0.26
(-0.66%)
1.86EPS
18.49P/E
19.47BMarket Cap
Apr 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.84
1.14
1.47
1.92
2.56
3.54
4.9
5.34
6.42
7.61
7.67
7.75
7.4
7.58
Basic EPS, GAAP
0.25
0.42
0.57
0.68
0.82
1.03
1.42
1.34
1.66
2
2.1
2.07
1.87
1.84
Free Cash Flow per Basic Share
0.06
0.16
0.18
0.35
0.05
0.45
0.15
-0.22
0.67
1.06
0.98
1.12
1.29
- -
Dividend per Share
0.04
0.1
0.13
0.01
0.78
0.56
0.63
0.7
0.67
0.75
0.83
1.08
1.27
1.31
Book Value per Share
1.65
2.42
1.46
3.01
3.05
3.53
4.68
11.05
12.41
13.27
14.56
14.83
15.62
15.79
Tangible Book Value per Share
1.56
2.34
1.43
2.98
2.33
2.84
3.87
10.34
11.74
12.65
13.97
14.31
14.74
14.7
Basic Weighted Avg Shares
489
492
488
511
548
546
547
558
587
584
580
577
571
573
Sales/Revenue/Turnover
409
563
716
980
1,400
1,930
2,679
2,978
3,766
4,442
4,444
4,471
4,226
4,339
Operating Margin (%)
33.41
41.46
43.34
39.98
35.32
33.9
34.34
28.84
26.49
27.79
29.26
28.43
27.31
27.49
Depreciation Expense
17
30
48
74
119
165
218
302
397
433
452
478
464
- -
Net Income, GAAP
124
208
278
350
447
563
774
748
974
1,167
1,217
1,194
1,068
1,056
Effective Tax Rate (%)
14.14
13.94
14.41
14.23
12.69
12.15
11.16
10.35
8.04
8.12
10.16
6.97
11.15
11
Profit Margin (%)
30.31
36.96
38.8
35.68
31.89
29.15
28.89
25.11
25.85
26.28
27.4
26.71
25.27
24.33
Working Capital
156
197
284
1,027
486
497
1,030
3,826
4,099
4,087
4,130
3,883
3,679
3,508
LT Debt
- -
31
70
- -
34
42
503
19
26
16
25
21
10
11
Total Equity
340
501
719
1,645
1,689
1,966
2,635
6,585
7,403
7,912
8,666
8,692
9,016
9,124
Return on Invested Capital (%)
38.93
44.28
38.44
27.04
25.92
30.01
28.84
15.01
13.67
15.11
13.99
12.42
11.84
11.84
Return on Capital (%)
43.21
47.61
41.24
28.51
26.33
29.28
28.49
14.93
13.55
14.86
14.14
12.99
11.6
11.81
Return on Common Equity (%)
43.21
49.5
45.6
29.6
26.96
31.29
34.52
16.55
14.16
15.5
14.92
13.93
12.18
12.08

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
62
48
32
LT Borrowings
- -
- -
- -
LT Finance Leases
7
8
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
571
571
571
Market Capitalization
19,114
16,583
19,474

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
6,093
5,513
5,930
Cash, Cash Equivalents & STI
984
1,254
1,539
Accounts Receivable, Net
1,111
1,146
1,227
Inventories
938
1,008
1,073
Total Current Liabilities
2,278
2,273
2,421
Payables & Accruals
- -
- -
- -
ST Debt
62
48
32
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.48%
6.57%
3.73%
Free Cash Flow
16.96%
-70.28%
14.34%
Net Income, GAAP
15.56%
8.38%
-10.59%
Sales/Revenue/Turnover
20.71%
7.92%
-5.47%
Total Cash Common Dividend
1,115.77%
13.47%
16.57%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,089
1,118
1,173
1,091
4,471
2025
996
1,064
- -
1,099
4,226
2026
992
1,066
1,182
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.56
0.51
0.59
0.42
2.07
2025
0.47
0.53
- -
0.36
1.87
2026
0.41
0.46
0.61
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
1.06
0.01
0.01
1.08
2025
0.01
1.26
- -
- -
1.27
2026
- -
1.31
- -
- -
- -

Company Description

CEO
Zeng Li Yang
Full Time Employees
5,700
Sector
Health technology
Industry
Medical specialties
Address
No. 199, 15th Avenue Zhengzhou HN China 450016
IPO Date
Sep 1, 2016
Business
Autobio Diagnostics Co., Ltd. (603658.SS) develops, manufactures, markets and services in vitro diagnostic reagents and instruments principally for immunoassay, microbiology, biochemistry, molecular diagnostics and coagulation testing; its core immunoassay offerings include chemiluminescence analyzers such as AutoLumo A6200/A6600 series, AutoLumo A2000 Plus, AutoLumo S900 and magnetic particle chemiluminescence reagents alongside ELISA and colloidal gold tests; microbiology products feature AutoMic-i600 ID-AST analyzer, AutoStreak S1800 sample pretreatment system, Autof T series and MALDI-TOF MS for pathogen identification, BC60/BC120 blood culture systems and susceptibility testing reagents; biochemistry lines comprise AutoChem B861/B2000 and Autolas Bi 1000/Bi2600 automated analyzers; molecular diagnostics cover AutoMolec 1600/3000 systems; coagulation analyzers include Ci-120x/Ci-310 models; and supporting services encompass technical support, training, internal quality control and AI-enhanced clinical decision systems for medical laboratories worldwide. Founded in 1998 and headquartered in Zhengzhou's National Eco & Tech Development Zone, China, the company operates domestically across thousands of medical institutions and exports to over 100 countries in Europe, Asia, the Middle East, South America and Africa, employing over 5,700 staff with R&D comprising about 30% and generating RMB 44.71 billion in 2024 revenue rising to RMB 31.27 billion in the first three quarters of 2025. Recent developments include strategic partnership with Boditech Med Inc in January 2025, hosting the Global MicroLabTalk Forum 2025 with IFCC and the 9th International Distributor Forum in Dubai, launching products like AutoLumo S900 and Autof T series at Medlab Middle East 2025, AutoChem B2000 winning the German iF Design Award 2025, expanding IVDR CE certificates to 326 and integrating DeepSeek-R1 AI into its clinical decision system; the firm listed on the Shanghai Stock Exchange main board in 2016 as China's first IVD manufacturer in that category.